The drug combines sumatriptan, a migraine-specific drug that affects the constriction of blood vessels, with naproxen sodium, a non-steroidal anti-inflammatory drug that works on the inflammatory aspect of migraine and relieves non-traditional migraine symptoms such as sinus pain and pressure and neck pain.
“Unfortunately, many migraine sufferers put off treatment,” said study author Stephen Silberstein, MD, of Thomas Jefferson University in Philadelphia, PA, and a Fellow of the American Academy of Neurology. “This study provides more evidence that treating a migraine at the first sign of pain increases the likelihood of relief.”
The research involved two studies with a total of 1,111 people with migraine who had experienced two to six attacks per month in the three months before the study started. Half of the people were given the sumatriptan/naproxen drug within an hour after migraine pain started and while the pain was still mild; the other half were given a placebo.
Two hours after the dose was given, about 50 percent of those who received the drug were free of any pain, compared to about 16 percent of those who got the placebo. The people who took the placebo were also two to three times more likely to progress to moderate or severe pain over four hours than those who took the drug.
Those who took the drug also had fewer traditional migraine-related symptoms such as nausea and sensitivity to light and sound and fewer non-traditional symptoms such as neck and sinus pain than those who took the placebo.
Silberstein noted that only people whose migraines had a mild pain phase were included in the study, so it is not clear whether the results would apply to people whose migraines start at the moderate or severe pain level.
The studies were sponsored by POZEN, Inc., and supported by GlaxoSmithKline.
The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer’s disease, epilepsy, Parkinson’s disease, and multiple sclerosis.
Angela Babb | American Academy of Neurology
Bioenergy cropland expansion could be as bad for biodiversity as climate change
11.12.2018 | Senckenberg Forschungsinstitut und Naturmuseen
How glial cells develop in the brain from neural precursor cells
11.12.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
Scientists at the University of Stuttgart and the Karlsruhe Institute of Technology (KIT) succeed in important further development on the way to quantum Computers.
Quantum computers one day should be able to solve certain computing problems much faster than a classical computer. One of the most promising approaches is...
New Project SNAPSTER: Novel luminescent materials by encapsulating phosphorescent metal clusters with organic liquid crystals
Nowadays energy conversion in lighting and optoelectronic devices requires the use of rare earth oxides.
Scientists have discovered the first synthetic material that becomes thicker - at the molecular level - as it is stretched.
Researchers led by Dr Devesh Mistry from the University of Leeds discovered a new non-porous material that has unique and inherent "auxetic" stretching...
10.12.2018 | Event News
06.12.2018 | Event News
03.12.2018 | Event News
11.12.2018 | Physics and Astronomy
11.12.2018 | Materials Sciences
11.12.2018 | Information Technology